ArticlePloS one2026
Association between muscle relaxant dosage and recovery in pediatric otolaryngological surgery: A retrospective cohort study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStandardized guidelines for dosing strategies of muscle relaxants-specifically aimed at reducing extubation time and side effects-are currently lacking in pediatric otolaryngological surgery. This retrospective cohort study examined the association between induction dosages of neuromuscular blocking drugs and extubation times in children undergoing ambulatory procedures, aiming to provide evidence for future clinical decision-making.
objectiveThis study examined the association between induction doses of muscle relaxants and two key outcomes in pediatric otolaryngological surgery: extubation times and the incidence of neuromuscular blockade-related complications (particularly residual paralysis and its clinical consequences, such as reintubation). The goal was to provide evidence that can inform dosing strategies aimed at accelerating recovery and minimizing adverse events.
methodsA retrospective review was conducted using electronic medical records of pediatric patients who underwent otolaryngological surgery at Shenzhen Hospital, Southern Medical University;data access for research purposes occurred between June 23, 2020, and June 23, 2021. A total of 90 children, aged 3-12 and classified as ASA I-II, was included in this study. The patients were categorized into three groups based on the muscle relaxant used during surgery: R1 (0.4 mg/kg rocuronium bromide), R2 (0.6 mg/kg rocuronium bromide), and C (0.05 mg/kg cisatracurium). Extracted parameters included mean blood pressure (MBP), heart rate (HR), blood oxygen saturation (SpO₂), Cooper scores, Ramsay Sedation Scale (RSS), Agitation Scale (AS), extubation time, and surgery duration.
resultsThe R2 group showed significantly higher mean blood pressure (MBP) than both R1 and C at T1 (both P < 0.05), and higher MBP than R1 and C at T2 (P < 0.01 and P < 0.05, respectively). Heart rate was significantly higher in both rocuronium groups compared to C at T1 and T2 (all P < 0.01). Cooper scores were significantly higher in R2 than in R1 or C (P < 0.01). No significant differences were found in SpO₂ at any time point (including T3 and T4), extubation time, surgery duration, RSS, or AS among groups (P > 0.05). No adverse events were observed in any of the three groups.
conclusionDespite the absence of pharmacological reversal, no clinical manifestations of residual neuromuscular blockade-including hypoxemia, reintubation, or severe emergence agitation-were observed in any group.Notably, rocuronium 0.6 mg/kg exhibited rapid onset, superior intubation conditions, and hemodynamic stability; extubation times and emergence quality were comparable among all groups receiving a single intubating dose of 1-1.5 × ED₉₅ of a neuromuscular blocking agent under the same intravenous-inhalation combined anesthesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.